Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00175825 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Phase 2 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT00175825 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 210 participants.
The verdict
NCT00175825, a Phase 2 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
Interventions
- OTHER Placebo
- DRUG Brivaracetam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2005-11-07 |
| Est. Completion | 2006-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00175825
The ClinicalTrials.gov registry entry for NCT00175825 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00175825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00175825 about?
NCT00175825 is a clinical study titled "A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.". This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
What is the current status of trial NCT00175825?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2005-11-07. Estimated completion is 2006-06-29.
What interventions are being tested in trial NCT00175825?
The interventions under investigation include: Placebo (OTHER), Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT00175825?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.